OBJECTIVES: We hypothesized that an integrated assessment of arginine with its catabolic products might better predict cardiovascular risks than arginine levels alone. BACKGROUND: Arginine is the sole nitrogen source for nitric oxide (NO) synthesis. The major catabolic products of arginine are ornithine and citrulline. METHODS: Plasma levels of free arginine, ornithine, citrulline, and the endogenous NO synthase inhibitor asymmetric dimethylarginine (ADMA) were measured with liquid chromatography coupled with tandem mass spectrometry. We examined the relationship of global arginine bioavailability ratio (GABR) (defined as arginine/[ornithine + citrulline]) versus arginine and its catabolic metabolites to prevalence of significantly obstructive coronary artery disease (CAD) and incidence of major adverse cardiovascular events (MACE) (death, myocardial infarction, stroke) over a 3-year follow-up in 1,010 subjects undergoing elective cardiac catheterization. RESULTS: Patients with significantly obstructive CAD had significantly lower GABR (median [interquartile range]: 1.06 [0.75 to 1.31] vs. 1.27 [0.96 to 1.73], p < 0.001) and arginine levels [mean: 68 +/- 20 micromol/l vs. 74 +/- 24 micromol/l, p < 0.001) than those without significantly obstructive CAD. After adjusting for Framingham risk score, C-reactive protein, and renal function, lower GABR (but not arginine levels) and higher citrulline levels remained significantly associated with both the prevalence of significantly obstructive CAD (adjusted odds ratio: 3.93, p < 0.001, and 5.98, p < 0.001, respectively) and 3-year risk for the incidence of MACE (adjusted hazard ratio: 1.98, p = 0.025, and 2.40, p = 0.01, respectively) and remained significant after adjusting for ADMA. CONCLUSIONS: GABR might serve as a more comprehensive concept of reduced NO synthetic capacity compared with systemic arginine levels. Diminished GABR and high citrulline levels are associated with both development of significantly obstructive atherosclerotic CAD and heightened long-term risk for MACE.
OBJECTIVES: We hypothesized that an integrated assessment of arginine with its catabolic products might better predict cardiovascular risks than arginine levels alone. BACKGROUND:Arginine is the sole nitrogen source for nitric oxide (NO) synthesis. The major catabolic products of arginine are ornithine and citrulline. METHODS: Plasma levels of free arginine, ornithine, citrulline, and the endogenous NO synthase inhibitor asymmetric dimethylarginine (ADMA) were measured with liquid chromatography coupled with tandem mass spectrometry. We examined the relationship of global arginine bioavailability ratio (GABR) (defined as arginine/[ornithine + citrulline]) versus arginine and its catabolic metabolites to prevalence of significantly obstructive coronary artery disease (CAD) and incidence of major adverse cardiovascular events (MACE) (death, myocardial infarction, stroke) over a 3-year follow-up in 1,010 subjects undergoing elective cardiac catheterization. RESULTS:Patients with significantly obstructive CAD had significantly lower GABR (median [interquartile range]: 1.06 [0.75 to 1.31] vs. 1.27 [0.96 to 1.73], p < 0.001) and arginine levels [mean: 68 +/- 20 micromol/l vs. 74 +/- 24 micromol/l, p < 0.001) than those without significantly obstructive CAD. After adjusting for Framingham risk score, C-reactive protein, and renal function, lower GABR (but not arginine levels) and higher citrulline levels remained significantly associated with both the prevalence of significantly obstructive CAD (adjusted odds ratio: 3.93, p < 0.001, and 5.98, p < 0.001, respectively) and 3-year risk for the incidence of MACE (adjusted hazard ratio: 1.98, p = 0.025, and 2.40, p = 0.01, respectively) and remained significant after adjusting for ADMA. CONCLUSIONS:GABR might serve as a more comprehensive concept of reduced NO synthetic capacity compared with systemic arginine levels. Diminished GABR and high citrulline levels are associated with both development of significantly obstructive atherosclerotic CAD and heightened long-term risk for MACE.
Authors: Claudia R Morris; Mirjana Poljakovic; Lisa Lavrisha; Lorenzo Machado; Frans A Kuypers; Sidney M Morris Journal: Am J Respir Crit Care Med Date: 2004-04-07 Impact factor: 21.405
Authors: Jan T Kielstein; Burcu Impraim; Solveig Simmel; Stefanie M Bode-Böger; Dimitrios Tsikas; Jürgen C Frölich; Marius M Hoeper; Hermann Haller; Danilo Fliser Journal: Circulation Date: 2003-12-08 Impact factor: 29.690
Authors: Christoph V Suschek; Oliver Schnorr; Karsten Hemmrich; Olivier Aust; Lars-Oliver Klotz; Helmut Sies; Victoria Kolb-Bachofen Journal: Circulation Date: 2003-05-12 Impact factor: 29.690
Authors: Monique B Moss; Tatiana M C Brunini; Roberto Soares De Moura; Lúcia E Novaes Malagris; Norman B Roberts; J Clive Ellory; Giovanni E Mann; Antônio C Mendes Ribeiro Journal: Clin Sci (Lond) Date: 2004-10 Impact factor: 6.124
Authors: Junghee Lee; Hoon Ryu; Robert J Ferrante; Sidney M Morris; Rajiv R Ratan Journal: Proc Natl Acad Sci U S A Date: 2003-03-24 Impact factor: 11.205
Authors: Zhili Shao; Zeneng Wang; Kevin Shrestha; Akanksha Thakur; Allen G Borowski; Wendy Sweet; James D Thomas; Christine S Moravec; Stanley L Hazen; W H Wilson Tang Journal: J Am Coll Cardiol Date: 2012-03-27 Impact factor: 24.094
Authors: Clifford L Cua; Lynette K Rogers; Louis G Chicoine; Molly Augustine; Yi Jin; Patricia L Nash; Leif D Nelin Journal: Eur J Pediatr Date: 2010-12-01 Impact factor: 3.183
Authors: Matthew J Kan; Jennifer E Lee; Joan G Wilson; Angela L Everhart; Candice M Brown; Andrew N Hoofnagle; Marilyn Jansen; Michael P Vitek; Michael D Gunn; Carol A Colton Journal: J Neurosci Date: 2015-04-15 Impact factor: 6.167
Authors: Claudia R Morris; Hae-Young Kim; Elizabeth S Klings; John Wood; John B Porter; Felicia Trachtenberg; Nancy Sweeters; Nancy F Olivieri; Janet L Kwiatkowski; Lisa Virzi; Kathryn Hassell; Ali Taher; Ellis J Neufeld; Alexis A Thompson; Sandra Larkin; Jung H Suh; Elliott P Vichinsky; Frans A Kuypers Journal: Br J Haematol Date: 2015-04-24 Impact factor: 6.998
Authors: W H Wilson Tang; Kevin Shrestha; Zeneng Wang; Richard W Troughton; Allan L Klein; Stanley L Hazen Journal: J Card Fail Date: 2013-02 Impact factor: 5.712
Authors: Claudia R Morris; Hae-Young Kim; John Wood; John B Porter; Elizabeth S Klings; Felicia L Trachtenberg; Nancy Sweeters; Nancy F Olivieri; Janet L Kwiatkowski; Lisa Virzi; Sylvia T Singer; Ali Taher; Ellis J Neufeld; Alexis A Thompson; Vandana Sachdev; Sandra Larkin; Jung H Suh; Frans A Kuypers; Elliott P Vichinsky Journal: Haematologica Date: 2013-04-12 Impact factor: 9.941
Authors: Edward Yu; Miguel Ruiz-Canela; Cristina Razquin; Marta Guasch-Ferré; Estefania Toledo; Dong D Wang; Christopher Papandreou; Courtney Dennis; Clary Clish; Liming Liang; Monica Bullo; Dolores Corella; Montserrat Fitó; Mario Gutiérrez-Bedmar; José Lapetra; Ramón Estruch; Emilio Ros; Montserrat Cofán; Fernando Arós; Dora Romaguera; Lluis Serra-Majem; Jose V Sorlí; Jordi Salas-Salvadó; Frank B Hu; Miguel A Martínez-González Journal: Diabetes Obes Metab Date: 2018-10-02 Impact factor: 6.577
Authors: Xin-Min Li; Wai Hong Wilson Tang; Marian K Mosior; Ying Huang; Yuping Wu; William Matter; Vivian Gao; David Schmitt; Joseph A Didonato; Edward A Fisher; Jonathan D Smith; Stanley L Hazen Journal: Arterioscler Thromb Vasc Biol Date: 2013-03-21 Impact factor: 8.311